Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure Company’s first-in-class technology has demonstrated significant, enduring reduction in pain and improvement in quality of life in ongoing PoC study to date THE WOODLANDS, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical dev ...

Access the Virtual Investor "What This Means" Segment here THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced that it recently participated in a Virtual Investor "What This Means" segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced 4-6 week positive follow-up data, f ...

Autonomix Medical, Inc. (AMIX) shared positive preliminary results from its first five lead-in patients in a proof-of-concept trial. The trial assesses the safety and effectiveness of Autonomix's proprietary radiofrequency (RF) ablation technology, designed to ablate targeted nerves and reduce pain in late-stage pancreatic cancer patients. Among participants, three treated through femoral access experienced significant pain reduction — from a mean score of 8 to 1.33 on the Visual Analog Scale — and were abl ...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.The Dow traded up 0.52% to 42,333.84 while the NASDAQ rose 0.43% to 18,598.02. The S&P 500 also rose, gaining, 0.31% to 5,826.12.Check This Out: How To Earn $500 A Month From Ford Stock Ahead Of Q3 EarningsLeading and Lagging SectorsUtilities shares rose by 1.1% on Monday.In trading on Monday, energy shares fell by 1%.Top HeadlineON Semiconductor Corp ON posted better-than-expected earnings for ...

Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro. The nano-cap firm focused on developing technologies for the nervous system revealed preliminary results from the first five "lead-in" patients in the company's ongoing proof-of-concept human trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigat ...

THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced that it will release a Virtual Investor "What This Means" segment on Wednesday, October 30, 2024. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix will discuss additional findings from the 4-6 week follow-up data from the first five "lead-in" patients in the Company ...

THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 11:59 pm (Eastern Time) on October 24, 2024, a ...

Live webcast fireside chat on Tuesday, October 15th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, CEO of Autonomix, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October ...

THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced it has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum taking place on October 8-9, 2024 in Irvine, California. The Octane Medical Innovation Forum brings together industry experts, entrepreneurs, investors and thought leaders for two days of l ...

Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company's ongoing proof-of-concept (PoC) human clinical trial THE WOODLANDS, TX, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced its technology and interim clinical trial findings will be featured in a pod ...